Streetbeat News

Regulatory

SNDX

Syndax Pharmaceuticals reported its Q3 2024 financial results and provided a business update. Key highlights include new clinical data for revumenib and Niktimvo to be presented at the ASH Annual Meeting, expected topline data for mNPM1 AML from AUGMENT-101 in Q4 2024, and a potential sNDA filing in 1H 2025. Revumenib's NDA for R/R KMT2Ar acute leukemia is under review with a PDUFA date of December 26, 2024. Niktimvo has been approved by the FDA for chronic GVHD treatment, and a $350 million royalty funding agreement is expected to support the company through profitability.

Portfolio Pulse from

November 05, 2024 | 9:15 pm

BEN

Franklin Resources, Inc. (NYSE:BEN) is under investigation by Bleichmar Fonti & Auld LLP for potential securities fraud following a CFTC inquiry. Investors are encouraged to seek more information if they have suffered losses.

Portfolio Pulse from

November 05, 2024 | 9:00 pm

MYO

Myomo's business model has become sustainable due to CMS reclassifying MyoPro, leading to lump sum payments and consistent insurance coverage. Medicare Part B coverage has improved Myomo's operating margin and accelerated product sales growth. The development of an Orthopedic and Prosthetic clinic network will lower customer acquisition costs and create recurring sales, enhancing long-term growth and margins.

Portfolio Pulse from

November 05, 2024 | 8:45 pm

ALVOF

Alvopetro is capitalizing on its first mover advantage in Brazil's evolving gas market, following the implementation of the New Gas Law in 2021, which aims to transform the sector.

Portfolio Pulse from

November 05, 2024 | 8:00 pm

ADM

Archer-Daniels-Midland (ADM) is facing accounting concerns, leading to the restatement of previous results and the cancellation of an earnings conference call. This has caused a drop in ADM's stock price.

Portfolio Pulse from

November 05, 2024 | 8:00 pm

AMZN

Amazon's Mk30 delivery drone has received FAA approval to begin operations, marking a significant step in the company's logistics and delivery capabilities.

Portfolio Pulse from

November 05, 2024 | 7:30 pm

BOOM

Johnson Fistel, LLP is investigating DMC Global Inc. for potential securities law violations, focusing on possible misrepresentations or failures to disclose material information.

Portfolio Pulse from

November 05, 2024 | 7:00 pm

USO

Crude oil prices are expected to be volatile post-U.S. election due to energy policy, Middle East conflicts, and Chinese economic stimulus. Gasoline prices are bearish, but the election and geopolitical factors could change this. The election outcome will influence energy policy, with Harris favoring renewables and Trump supporting hydrocarbons.

Portfolio Pulse from

November 05, 2024 | 6:45 pm

MRUS

Merus is approaching a significant milestone with the potential FDA approval of zenocutuzumab for NRG1+ NSCLC/PDAC, with a PDUFA date set for February 4, 2025. Additionally, promising data for Petosemtamab targeting HNSCC will be presented in December 2024. The company is financially stable with $782.9 million in cash and has strategic partnerships with major pharmaceutical companies.

Portfolio Pulse from

November 05, 2024 | 6:30 pm

SMCI

Super Micro Computer (SMCI) is preparing to report its earnings, aiming to reverse its recent stock decline and address concerns about its accounting practices.

Portfolio Pulse from

November 05, 2024 | 6:00 pm